Vertex Pharmaceuticals Inc (VRTX)

Sep 25, 2026

A Delaware federal court has ruled that generic drugmakers Teva Pharmaceuticals and Apotex Inc. do not infringe patents held by Vanda Pharmaceuticals for its sleep drug Hetlioz. This decision allows Teva and Apotex to potentially market generic versions of the medication without facing patent infringement claims from Vanda. The ruling is a significant development in the pharmaceutical industry for these companies.

Sep 24, 2026

Shares of Vertex Pharmaceuticals Inc. (VRTX) rose 1.17% to $522.38 on Thursday, outperforming the broader stock market which saw the S&P 500 Index and Dow Jones Industrial Average decline. This marked the fourth consecutive day of gains for the stock.

Sep 23, 2026

Vertex Pharmaceuticals announced positive results from its Phase IIb AMPLIFIED trial for inaxaplin, treating APOL1-mediated kidney disease (AMKD) in patients with modest proteinuria and type 2 diabetes. The drug demonstrated significant reductions in proteinuria and was well-tolerated across both cohorts. These findings support the potential for inaxaplin as a treatment targeting the underlying cause of AMKD, with further data expected from the pivotal AMPLITUDE study in early 2027.

Sep 22, 2026

Vertex Pharmaceuticals (VRTX) is gaining renewed attention in the healthcare sector due to company-specific clinical and regulatory catalysts, particularly its focus on medicines for serious genetic diseases. The market is shifting its focus to specialty-drug durability within a defensive sector, presenting both opportunities and risks for VRTX. Investors are advised to look for concrete updates connecting this theme to Vertex's operations, as market enthusiasm needs to be backed by execution and specific evidence.

Sep 22, 2026

This article analyzes Boston Scientific (BSX) within the context of the broader healthcare stocks market, highlighting how specific clinical and regulatory catalysts have revived interest in medical technology. It emphasizes the importance of a company-specific reading, rather than treating BSX merely as a sector proxy, to understand its performance in medical devices across various specialties. The piece concludes by noting that while market enthusiasm is evident, investors should look for concrete operational updates from Boston Scientific to confirm whether the current attention is supported by execution.

Sep 21, 2026

Ali Behbahani, a director at CRISPR Therapeutics, sold 13,679 shares of NASDAQ:CRSP stock for over $780,000, reducing his position by 45.12%. Despite this insider selling, the stock rose 3.1%, and analysts maintain a "Moderate Buy" rating with an average price target of $67.94. The company reported a quarterly loss and analysts expect a full-year loss, while institutional investors hold a significant 69.2% stake.

Sep 21, 2026

CRISPR Therapeutics stock has had a disappointing performance recently, but the company's gene-editing drug, Casgevy, is accruing revenue set to be reported next year. Beyond Casgevy, CRISPR Therapeutics has a promising pipeline of other treatments and its patented gene-editing technology has significant long-term potential. These factors suggest the stock remains an attractive investment for those comfortable with the inherent risks of biotech.

Sep 17, 2026

This article compares Amgen and Vertex Pharmaceuticals to determine which healthcare stock is a better investment in 2026. While Amgen offers stability and a diversified portfolio, Vertex Pharmaceuticals is highlighted for its high-growth potential, dominant position in cystic fibrosis, expanding pipeline, and superior operating margins. The author ultimately recommends Vertex for long-term investors seeking growth in the healthcare sector.

Sep 15, 2026

This article compares Amgen (AMGN) and Vertex Pharmaceuticals (VRTX), two biotech companies, highlighting their divergent investment profiles: Amgen as a mature, diversified pharmaceutical firm offering stability and dividends, and Vertex as a high-growth, specialized biotech focused on rare diseases. It analyzes both companies across profitability, risk profile, and valuation, concluding that the choice depends on an investor's preference for stable returns versus high-growth potential.